Drug
Pemigatinib
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Tyrosine Kinase Inhibitors (TKIs) |
| Group | FGFR targeting TKI |
| Mechanism of Action | FGFR inhibitor |
| Half-life | 15.4 h |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing in FGFR-dependent tumors (↓MAPK/PI3K-AKT, nuclear PTEN) (Fisher et al., International Journal of Radiation Oncology, Biology, Physics, 2020; SenthilKumar et al., Molecular Cancer Therapeutics, 2020). Sensitization tracks pathway dependence rather than ubiquitous expression, so added normal-tissue side-effects is theoretically modest, though the class's baseline mucocutaneous/nail effects could overlap with in-field skin/mucosal reactions.
Data on this page refer exclusively to patients treated with
Pemigatinib combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
FGFR targeting TKI group page.